Thomas H. Kean
Suspicious Timing Detected
5 flagsRep. Thomas H. Kean sold $1,001 - $15,000 in $GM on January 7, 2026, 15 days before HR7085, which repeals conflict mineral disclosure requirements, was placed on the Union Calendar.
Rep. Thomas H. Kean sold $15,001 - $50,000 in $JNJ on January 23, 2026, 18 days before S3822, the 'Break Up Big Medicine Act,' was introduced, aiming to prohibit common ownership between pharmaceutical companies.
Rep. Thomas H. Kean sold $15,001 - $50,000 in $SYK on January 23, 2026, 19 days before HR7493, the 'Stop Corporate Inversions Act of 2026,' which aims to increase the tax burden on companies that have inverted.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABT | Abbott Laboratories Common Stock | $1K-$15K | — | — | — | Jan 29, 2026 |
| PARTIAL SELL | $JNJ | Johnson & Johnson Common Stock | $15K-$50K | — | — | — | Jan 23, 2026 |
| PARTIAL SELL | $MKL | Markel Group Inc. Common Stock | $15K-$50K | — | — | — | Jan 23, 2026 |
| PARTIAL SELL | $SYK | Stryker Corporation Common Stock | $15K-$50K | — | — | — | Jan 23, 2026 |
| SELL | $GM | General Motors Company Common Stock | $1K-$15K | — | — | — | Jan 7, 2026 |
| PARTIAL SELL | $MSFT | Microsoft Corporation - Common Stock | $1K-$15K | — | — | — | Jan 23, 2026 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Safety is Not For Sale Act
The 'Safety is Not For Sale Act' (HR7372) has advanced out of subcommittee, mandating the unbundling of safety features from non-safety features in motor vehicle sales. This legislative action directly impacts automotive manufacturers' sales models, potentially reducing revenue from bundled luxury packages. Recent market data shows significant 30-day declines for $TSLA (-13%) and $HMC (-13.21%), while $GM (-3.64%), $F (-5.92%), and $TM (-7.7%) also experienced declines, and $STLA gained 2.89%.
GAP Supply Act
The GAP Supply Act (HR7528) was introduced on February 12, 2026, and referred to the House Committee on Energy and Commerce. This bill aims to allow outsourcing facilities to continue supplying drugs during shortages for an additional 180 days, providing regulatory stability for pharmaceutical supply chains. The bill is in an early legislative stage.
Break Up Big Medicine Act
The 'Break Up Big Medicine Act' (S.3822), introduced by Senator Warren and cosponsored by Senator Hawley, aims to prohibit common ownership between pharmacy benefit managers, insurers, drug/medical device wholesalers, and certain medical service providers. This bill, currently in the early stages of being referred to the Committee on the Judiciary, targets the vertical integration prevalent in the healthcare sector, potentially forcing divestitures for large pharmaceutical and healthcare conglomerates. While the bill does not specify direct funding, its provisions could significantly restructure the healthcare market.
To amend the Securities Exchange Act of 1934 to repeal certain disclosure requirements related to conflict minerals, and for other purposes.
HR7085, which repeals conflict mineral disclosure requirements, has been placed on the Union Calendar. This regulatory relief reduces compliance costs for electronics and automotive manufacturers. Companies like Apple, Microsoft, and Tesla are direct beneficiaries of this reduced reporting burden.
AI Grand Challenges Act of 2026
The AI Grand Challenges Act of 2026 (S.3809) has been introduced in the Senate and referred to committee. This bill authorizes the National Science Foundation to establish a competitive prize program for AI research and development across various sectors, including national security, health, and energy, but does not appropriate funds. While the bill signals potential future government investment in AI, its early legislative stage and lack of direct funding appropriation mean immediate market impact is limited.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026, S3847, aims to increase U.S. tax liabilities for companies that have inverted or plan to invert, potentially reducing net income for affected corporations. This bill is in the early stages, having been referred to the Senate Committee on Finance on February 11, 2026. Companies with significant foreign operations that have previously inverted or might consider it face increased tax burdens if this legislation progresses.
Driver Technology and Pedestrian Safety Act of 2025
HR3360 initiates a study on the impact of touch screen-based driver technology on traffic safety. This bill creates no immediate regulatory changes or market shifts, but establishes a foundation for future policy impacting automotive and technology companies.
PART Act
The PART Act, HR5221, mandates new motor vehicles to include catalytic converter identification, increasing manufacturing costs for all new vehicles sold in the U.S. This bill does not involve direct appropriations or immediate market shifts, but creates a new regulatory requirement for automakers. The bill is currently active, having been forwarded by a Subcommittee to a Full Committee by Voice Vote on 2026-02-10.
Stop Corporate Inversions Act of 2026
The Stop Corporate Inversions Act of 2026 (HR7493) aims to increase the tax burden on companies that have inverted or are considering inversion, particularly in the healthcare and technology sectors, by tightening ownership requirements. This legislation, if enacted, would make future inversions financially unviable and reduce profitability for affected companies. The bill is in an early stage, having been referred to the House Committee on Ways and Means on February 11, 2026.
CMMSA 2.0
CMMSA 2.0 significantly increases tax credits for domestic battery component production and expands eligible materials, directly boosting U.S. and allied manufacturing. This legislation creates a clear competitive advantage for domestic producers by excluding materials from 'prohibited foreign entities' after December 31, 2026. Companies involved in U.S. lithium, cobalt, manganese, silicon, and graphite processing and battery manufacturing will see increased profitability and demand.
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.